logo-loader
viewFutura Medical PLC

Futura Medical's James Barder says regulatory submissions for MED3000 remain on track

Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track.

The treatment is MED3000 - a fast-acting gel that will be targeted at men for whom the current treatments don’t work.

Barder says a second pre-submission meeting with the US Food & Drug Administration has been now set.

Quick facts: Futura Medical PLC

Price: 15.5 GBX

AIM:FUM
Market: AIM
Market Cap: £38.07 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical gets set to begin formal approval steps for erectile...

Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction. Proceedings have begun for formal approval of the drug to be approved as a...

2 days, 14 hours ago

2 min read